Integra LifeSciences Holdings Corporation $IART Position Decreased by JPMorgan Chase & Co.

Key Points

• JPMorgan cut its stake in Integra LifeSciences by 92.9% in Q3, selling 7,249,229 shares and leaving it with 551,732 shares (about 0.71% of the company) worth roughly $7.9 million.
• Integra reported quarterly EPS $0.83 (above estimates) and revenue of $434.9M, but still showed a negative net margin (−31.58%) and year‑over‑year revenue decline of 1.7%; management set FY2026 guidance of EPS 2.30–2.40.
• Analyst sentiment is mixed-to-negative with an average rating of "Reduce" (1 Buy, 2 Hold, 3 Sell) and an average target price of $14.40, while the stock trades around $9.12 with a market cap near $711M and a 52‑week range of $8.70–$22.27.

JPMorgan Chase & Co. reduced its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 92.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 551,732 shares of the life sciences company's stock after selling 7,249,229 shares during the quarter. JPMorgan Chase & Co. owned 0.71% of Integra LifeSciences worth $7,906,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in Integra LifeSciences by 55.3% in the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company's stock worth $37,000 after buying an additional 913 shares during the last quarter. Osaic Holdings Inc. boosted its stake in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company's stock worth $51,000 after acquiring an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company's stock worth $98,000 after acquiring an additional 6,814 shares during the last quarter. Amundi grew its holdings in shares of Integra LifeSciences by 17,193.8% in the 2nd quarter. Amundi now owns 11,068 shares of the life sciences company's stock worth $150,000 after acquiring an additional 11,004 shares during the last quarter. Finally, Inceptionr LLC acquired a new stake in shares of Integra LifeSciences during the third quarter worth $164,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

NASDAQ IART opened at $9.12 on Tuesday. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. The firm has a market capitalization of $710.81 million, a price-to-earnings ratio of -1.36 and a beta of 1.02. The company has a 50 day simple moving average of $10.60 and a 200-day simple moving average of $12.39. Integra LifeSciences Holdings Corporation has a 52-week low of $8.70 and a 52-week high of $22.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm had revenue of $434.93 million for the quarter, compared to the consensus estimate of $429.62 million. During the same period in the previous year, the firm posted $0.97 earnings per share. The firm's revenue was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Equities research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IART has been the subject of a number of recent analyst reports. Wells Fargo & Company upgraded Integra LifeSciences to a "hold" rating in a research report on Wednesday, March 18th. Weiss Ratings restated a "sell (e+)" rating on shares of Integra LifeSciences in a report on Friday. Citigroup reduced their price objective on shares of Integra LifeSciences from $11.00 to $9.00 and set a "sell" rating for the company in a research note on Wednesday, March 11th. Finally, Wall Street Zen cut shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Integra LifeSciences currently has an average rating of "Reduce" and an average target price of $14.40.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.